TxCell names François Meyer as chief executive
Prepares to take lead product candidates into clinical trials
The company is preparing to further the development of its lead product candidate for the treatment of refractory Crohn’s disease patients into Phase IIb trials and move its second product candidate into a Phase I/II clinical trial for the treatment of refractory rheumatoid arthritis patients.
Meyer has more than 25 years of pharmaceutical and biotechnology experience. During the early part of his career, he held various executive positions in r&d at Ciba-Geigy Pharma, where he headed the Molecular Genetics department in the newly formed Biotechnology division and at Sandoz Pharma, where he led the Gene and Cell Therapy business.
After joining Rhone Poulenc Rorer in 1996, where he first headed r&d at Gencell, a biotechnology division of Rhone Poulenc Rorer, Meyer was promoted to head of Global Research in 1998 and became head of r&d at Aventis Pharma, France after the merger with Hoechst in 2000. Lately he was ceo of Centelion until 2006, a biopharmaceutical affiliate company of Aventis Pharma.
You may also like
Research & Development
TxCell Signs inlicensing agreement with Inserm Transfert for novel population of regulatory T cells
TxCell SA, a biotechnology company developing innovative, personalised cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, and Inserm Transfert, on behalf of Inserm, the Nantes University (Nantes, France) and the Nantes CHU, have announced the signature of an exclusive worldwide licensing agreement